JP2022513021A5 - - Google Patents

Info

Publication number
JP2022513021A5
JP2022513021A5 JP2021525809A JP2021525809A JP2022513021A5 JP 2022513021 A5 JP2022513021 A5 JP 2022513021A5 JP 2021525809 A JP2021525809 A JP 2021525809A JP 2021525809 A JP2021525809 A JP 2021525809A JP 2022513021 A5 JP2022513021 A5 JP 2022513021A5
Authority
JP
Japan
Prior art keywords
immunogenic peptide
amino acid
peptide according
antigen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513021A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/080929 external-priority patent/WO2020099356A2/en
Publication of JP2022513021A publication Critical patent/JP2022513021A/ja
Publication of JP2022513021A5 publication Critical patent/JP2022513021A5/ja
Pending legal-status Critical Current

Links

JP2021525809A 2018-11-12 2019-11-12 向上した酸化還元酵素モチーフを有する免疫原性ペプチド Pending JP2022513021A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18205611.9 2018-11-12
EP18205615.0 2018-11-12
EP18205611 2018-11-12
EP18205615 2018-11-12
PCT/EP2019/080929 WO2020099356A2 (en) 2018-11-12 2019-11-12 Immunogenic peptides with improved oxidoreductase motifs

Publications (2)

Publication Number Publication Date
JP2022513021A JP2022513021A (ja) 2022-02-07
JP2022513021A5 true JP2022513021A5 (https=) 2022-11-22

Family

ID=68655497

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525806A Pending JP2022513019A (ja) 2018-11-12 2019-11-12 新規の酸化還元酵素モチーフを有する免疫原性ペプチド
JP2021525809A Pending JP2022513021A (ja) 2018-11-12 2019-11-12 向上した酸化還元酵素モチーフを有する免疫原性ペプチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021525806A Pending JP2022513019A (ja) 2018-11-12 2019-11-12 新規の酸化還元酵素モチーフを有する免疫原性ペプチド

Country Status (18)

Country Link
US (2) US20210401976A1 (https=)
EP (2) EP3880237A2 (https=)
JP (2) JP2022513019A (https=)
KR (1) KR20210093933A (https=)
CN (2) CN113015541A (https=)
AU (2) AU2019377983B2 (https=)
BR (1) BR112021009210A2 (https=)
CA (2) CA3118620A1 (https=)
CO (1) CO2021007060A2 (https=)
CU (1) CU20210041A7 (https=)
IL (1) IL282849A (https=)
MX (1) MX2021005540A (https=)
PE (1) PE20211494A1 (https=)
PH (1) PH12021551101A1 (https=)
SG (1) SG11202104875XA (https=)
TW (1) TW202043255A (https=)
WO (2) WO2020099352A2 (https=)
ZA (1) ZA202102909B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
JP7102430B2 (ja) 2017-03-09 2022-07-19 アンシス・エスア 糖尿病の治療のためのペプチド及び方法
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
US20240189404A1 (en) * 2020-05-06 2024-06-13 Imcyse Sa Immunogenic peptides with extended oxidoreductase motifs
EP4146255A1 (en) * 2020-05-06 2023-03-15 Imcyse SA Immunogenic peptides with new oxidoreductase motifs
CN117750971A (zh) 2021-05-26 2024-03-22 易姆赛斯股份公司 治疗或预防自身免疫病的方法
AR126654A1 (es) * 2021-06-29 2023-11-01 Imcyse Sa Péptidos y métodos para el tratamiento de neuromielitis óptica
CN121378402A (zh) * 2025-06-12 2026-01-23 杭州湃肽生化科技有限公司 一种双环肽化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520803A (ja) * 2000-04-21 2004-07-15 コリクサ コーポレイション 尋常性挫瘡の治療および診断のための組成物および方法
WO2003055981A2 (en) * 2001-12-21 2003-07-10 University Of Rochester Methods of modulating heme oxygenase-1 expression and treating heme oxygenase-1 mediated conditions
WO2004011650A2 (en) * 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
ES2709176T3 (es) * 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
EP2245059B1 (en) 2008-02-14 2017-09-20 Life Sciences Research Partners VZW Cd4+ t-cells with cytolytic properties
ES2584430T3 (es) 2008-02-14 2016-09-27 Life Sciences Research Partners Vzw Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles
EP2106803A1 (en) * 2008-04-04 2009-10-07 Fondazione Centro San Raffaele del Monte Tabor Method to design and uses of overlapping peptides for monitoring T-cell responses in HIV patients
DE11787873T1 (de) 2010-11-25 2013-12-12 Imnate Sarl Immugene Peptide zur Verwendung bei der Vorbeugung und/oder Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Immunreaktionen auf Allofaktoren, allergischen Erkrankungen, Tumoren, Transplantatabstossungen und Immunreaktionen auf virale Vektoren
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) * 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) * 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
BR112018071466A2 (pt) * 2016-04-19 2019-03-19 Imcyse Sa novos peptídeos de ligação a cd1d imunogênicos
EP3388447A1 (en) * 2017-04-14 2018-10-17 Imnate Sarl Methods to produce peptides, polypeptides or cells for modulating immunity
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
US20240189404A1 (en) * 2020-05-06 2024-06-13 Imcyse Sa Immunogenic peptides with extended oxidoreductase motifs

Similar Documents

Publication Publication Date Title
JP2022513021A5 (https=)
JP2022513019A5 (https=)
CN103261218B (zh) 免疫原性肽在预防和/或治疗疾病中的应用
DK1581174T3 (en) Yeast-based vaccines such as immunotherapy
ES2328025T3 (es) Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb.
KR102228843B1 (ko) Cd4+ t-세포 반응의 증강을 위한 변형된 에피토프
PE20240645A1 (es) Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores
US20130028915A1 (en) Dendritic cell (dc)-vaccine therapy for pancreatic cancer
JP5709264B2 (ja) ワクチン組成物および方法
RU2017111657A (ru) Новые иммуногенные пептиды
JP2018504419A5 (https=)
US11352411B2 (en) Fusion peptides of CD4 helper T cell epitopes and vaccines thereof
EP2547360A1 (en) System and method of preparing and storing activated mature dendritic cells
Milani et al. Small heat shock protein 27: An effective adjuvant for enhancement of HIV-1 Nef antigen-specific immunity
EP1096953A1 (fr) Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, procede de preparation et applications pharmaceutiques ou vaccinales
Voskens et al. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome
WO2019210782A1 (zh) 辅助性表位肽及其应用
RU2021115718A (ru) Иммуногенные пептиды с улучшенными мотивами оксидоредуктазы
US20250009825A1 (en) Lysates of recombinant yeast for inducing cellular immune responses
JP2016534042A (ja) ユビキチニル化タンパク質
US10849967B2 (en) Nucleic acid molecules encoding for chimeric CSPG4 proteins and therapeutic uses thereof
Hiroshi et al. A Novel Hydrophobized Polysaccharide/Oncoprotein Complex Vaccine for Her2 Gene Expressing Cancer
AU7909700A (en) New lymphocytes, a process for preparing the same and their use in therapeutics
Shihab et al. Recombinant listeriolysin-O as a platform for next-generation vaccines: Mechanisms, immunological evidence, and translational applications in human and veterinary medicine
RU2020105192A (ru) Варианты фактор h-связывающего белка и способы их применения